Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial
ESMO Open · 2026-12 · 11 (12) · 108643
DOI: 10.1016/j.esmoop.2026.108643 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Open, 2026-12. Verfasst von A S Clark und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pennsylvania, Philadelphia, USA. Electronic address: Amy.Clark@pennmedicine.upenn.edu. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Breast Cancer Research Foundation Inc, William K Bowes Jr Foundation, Foundation for the National Institutes of Health.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Preclinical evidence suggests synergy between poly-ADP-ribose inhibitors and camptothecin chemotherapy. We tested the talazoparib and irinotecan combination (TI) in the neoadjuvant setting in the I-SPY2 trial in patients with HER2-negative locally advanced breast cancer. MATERIALS AND METHODS: I-SPY2 is a phase II platform trial for stage 2/3 early breast cancer at high risk of recurrence. Participants were adaptively randomized to one of several experimental neoadjuvant therapies or control based on receptor subtypes defined by hormone receptor (HR), HER2 status, and MammaPrint risk (MP1, MP2). The primary endpoint was pathological complete response (pCR). Treatments 'graduate' if/when they achieve an 85% Bayesian probability of success in a subtype-specific phase III trial. Only HER2-negative patients were eligible for randomization to the TI arm. All patients received weekly paclitaxel for 12 weeks, followed by doxorubicin/cyclophosphamide and surgery. Participants randomized to the TI arm received daily oral talazoparib and irinotecan infusions every other week. Pathway-specific biomarkers were assessed for response prediction. RESULTS: The combination of talazoparib and irinotecan failed to graduate from the I-SPY2 trial, with a 19% modeled posterior probability of pCR in the TI arm compared with 20% in the control arm among all patients with HER2-negative breast cancer. The most common adverse events were neutropenia and anemia in the TI arm and neuropathy and fatigue in the control arm. pCR rates were highest in patients with germline Breast Cancer Gene 1 or 2 (BRCA1/2) mutations receiving TI (pCR rate 50%) and in those with tumors expressing a DNA repair deficiency signature. CONCLUSIONS: TI will not be further explored as a combination given lack of improved efficacy over control (paclitaxel) for neoadjuvant treatment in patients with HER2-negative breast cancer. pCR rates were highest (50%) among patients with germline BRCA1/2 mutations, likely due to the efficacy of talazoparib alone. Further combinations could be explored in patients with HER2-negative breast cancer and a germline BRCA1/2 or PALB2 mutation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of Pennsylvania, Philadelphia, USA. Electronic address: Amy.Clark@pennmedicine.upenn.edu.
- Department of Medicine, Rutgers University, New Brunswick, USA.
- Department of Surgery, University of California San Francisco, San Francisco, USA.
- Department of Surgery, University of California San Diego, La Jolla, USA.
- Department of Medicine, University of Alabama at Birmingham, Birmingham, USA.
- Department of Medicine, University of California San Francisco, San Francisco, USA.
Förderung
- The Breast Cancer Research Foundation Inc
- William K Bowes Jr Foundation
- Foundation for the National Institutes of Health
- Safeway Foundation
- National Institutes of Health National Cancer Institute
Zitieren
APA
Clark, A. S., Omene, C., Yau, C., Wallace, A. M., Stringer-Reasor, E., Chien, A. J., Isaacs, C., Han, H. S., Albain, K. S., Boughey, J. C., Nanda, R., Beckwith, H., Mitri, Z., Ellis, E. D., Elias, A. D., Lang, J. E., Shatsky, R., Howard-McNatt, M., Helsten, T., …, & Esserman, L. J. (2026). Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial. ESMO Open, 11(12), 108643. https://doi.org/10.1016/j.esmoop.2026.108643
Vancouver
Clark AS, Omene C, Yau C, Wallace AM, Stringer-Reasor E, Chien AJ, et al. Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial. ESMO Open. 2026;11(12):108643. doi:10.1016/j.esmoop.2026.108643
BibTeX
@article{Clark2026,
author = {Clark, A S and Omene, C and Yau, C and Wallace, A M and Stringer-Reasor, E and Chien, A J and Isaacs, C and Han, H S and Albain, K S and Boughey, J C and Nanda, R and Beckwith, H and Mitri, Z and Ellis, E D and Elias, A D and Lang, J E and Shatsky, R and Howard-McNatt, M and Helsten, T and Blair, S and Woodard, S and Parker, C and Melisko, M and Crane, E P and Asare, A L and Brown-Swigart, L and Hirst, G L and Matthews, J B and Delson, A L and Perlmutter, J and Yee, D and DeMichele, A M and Rugo, H S and Hylton, N M and Symmans, W F and van 't Veer, L J and Berry, D A and Esserman, L J},
title = {Neoadjuvant talazoparib, irinotecan, and standard chemotherapy for early breast cancer in the I-SPY2 trial},
journal = {ESMO Open},
year = {2026},
volume = {11},
number = {12},
pages = {108643},
doi = {10.1016/j.esmoop.2026.108643}
}
EUVIMED